Barry is a Managing Director at Princeton Biopharma Capital Partners, LLC, with over 35 years of biotech and pharmaceutical industry experience combined with a distinguished scientific career.

Prior to joining Princeton Biopharma Capital Partners, Barry was Vice President of Business Development at Valeant Pharma North America LLC, responsible for the business development activities of its specialty pharmaceutical businesses in dermatology, CNS, orphan conditions, and ophthalmology. Before Valeant, he was a founding employee of Aton Pharma, Inc., a specialty pharmaceutical company with products that treated orphan conditions and ophthalmology. As its Vice President of Business Development, Barry identified and acquired several key products for Aton and put in place its international partnerships. In addition, he was responsible for recognizing opportunities to expand the application of Aton’s products to new medical uses and spearheaded programs to develop these new indications.

Before Aton, Barry was Founder and President of Park Life Science Advisory, LLC, where he provided outsourced business development capabilities for life science companies. He was previously a Managing Director at CPP Advisors (now Apeiron Partners), a boutique life sciences strategic advisory group, and before that a Director in the Life Sciences Group at KPMG Corporate Finance, LLP, an investment bank. For the 10 years prior to KPMG, Barry held increasingly senior positions in cardiovascular research and then in business development at Berlex Laboratories, the US subsidiary of Schering A.G. (now Bayer Healthcare Pharmaceuticals), most recently as Associate Director of Schering’s Office of Technology. Before Berlex, he initiated and developed the Protein Biochemistry Group at the biotech startup Ecogen and served as the company’s Radiation Safety Officer. Barry received his PhD and Master’s degrees in Molecular Biophysics and Biochemistry from Yale University and was granted his BA, with highest honors, in Biochemistry from Princeton University. His current board appointments include Fidelis Animal Health, Covis Pharmaceuticals and Mountain View Pharma.